Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Sequent Scientific
Join Channel
Consolidated Standalone

Sequent Scientific

₹117.2 1 | 0.8%

Market Cap ₹2923 Cr.

Stock P/E -22.7

P/B 4.5

Current Price ₹117.2

Book Value ₹ 25.7

Face Value 2

52W High ₹155.5

Dividend Yield 0%

52W Low ₹ 70.2

Edit Ratio

Sequent Scientific Research see more...

Overview Inc. Year: 1985Industry: Pharmaceuticals & Drugs

SeQuent Scientific Ltd is an India-based incorporated pharmaceutical business enterprise. The Company operates inside the domain names of animal health and analytical offerings. The animal health enterprise, Alivira, includes active pharmaceutical ingredient and finished dosage formulations. Its treatment plans targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti inflammatory tablets (NSAID), anti-infectives and dermatology. The Company's analytical solutions commercial enterprise is a agreement studies company specialized in analytical and bio analytical offerings to assist the active pharmaceutical component, pharmaceutical, personal care and nutraceutical groups. It presents entire analytical solutions consisting of method validation, stability, microbiology for energetic pharmaceutical components and completed merchandise in numerous dosage forms as according to pharmacopoeial monographs, patron developed methods or in-residence method improvement.

Read More..

Sequent Scientific Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Sequent Scientific Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 351 358 384 341 338 375 367 333 346 329
Other Income 1 4 4 1 1 3 2 1 2 5
Total Income 351 362 387 342 339 378 368 334 348 334
Total Expenditure 331 322 350 339 335 365 370 341 331 307
Operating Profit 20 40 37 3 4 13 -2 -7 17 27
Interest 3 3 6 7 8 10 11 10 13 13
Depreciation 13 13 13 14 13 14 15 14 15 15
Exceptional Income / Expenses 0 0 0 -3 0 0 -62 -24 8 3
Profit Before Tax 4 24 18 -21 -18 -10 -89 -56 -3 1
Provision for Tax -10 5 8 -6 -13 -0 4 -21 4 -9
Profit After Tax 14 19 10 -15 -4 -10 -92 -35 -7 11
Adjustments 0 -1 -1 0 1 1 -1 -0 -1 -2
Profit After Adjustments 14 17 9 -15 -4 -9 -94 -35 -8 8
Adjusted Earnings Per Share 0.6 0.7 0.4 -0.6 -0.2 -0.4 -3.8 -1.4 -0.3 0.3

Sequent Scientific Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 327 395 443 606 684 848 1039 1179 1362 1413 1421 1375
Other Income 3 4 10 13 11 17 9 10 10 11 6 10
Total Income 329 399 453 619 695 864 1048 1189 1372 1424 1427 1384
Total Expenditure 343 387 425 551 641 765 914 1009 1152 1303 1409 1349
Operating Profit -13 12 28 68 54 100 134 180 220 120 18 35
Interest 33 34 43 38 28 33 33 36 24 16 36 47
Depreciation 29 29 32 46 40 41 42 51 51 52 56 59
Exceptional Income / Expenses 0 -59 -17 0 0 -2 0 0 -9 0 -65 -75
Profit Before Tax -75 -110 -63 -15 -14 24 59 94 137 53 -138 -147
Provision for Tax -8 1 3 3 -1 13 2 12 32 8 -16 -22
Profit After Tax -67 -110 -67 -18 -14 10 57 82 104 45 -122 -123
Adjustments 2 -0 56 -1 0 411 -8 -12 -9 -4 1 -4
Profit After Adjustments -65 -110 -11 -18 -14 422 49 70 95 41 -121 -129
Adjusted Earnings Per Share -5.5 -8.3 -0.7 -0.8 -0.6 17.3 2 2.8 3.8 1.6 -4.9 -5.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 1% 6% 11% 16%
Operating Profit CAGR -85% -54% -29% 0%
PAT CAGR -371% NAN% NAN% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 50% -26% 11% 9%
ROE Average -19% 1% 5% -37%
ROCE Average -10% 5% 7% 1%

Sequent Scientific Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 95 57 91 946 977 648 707 687 728 692 699
Minority's Interest 5 5 147 2 17 37 40 45 49 48 50
Borrowings 138 151 250 211 165 104 148 150 94 122 183
Other Non-Current Liabilities 6 8 27 88 81 124 67 66 60 87 75
Total Current Liabilities 345 405 406 290 545 431 440 515 513 537 559
Total Liabilities 589 626 922 1538 1904 1343 1402 1463 1443 1487 1566
Fixed Assets 227 238 474 586 684 476 498 577 536 564 605
Other Non-Current Assets 131 122 138 461 492 329 298 162 141 114 138
Total Current Assets 231 266 310 476 594 538 606 724 767 808 812
Total Assets 589 626 922 1538 1904 1343 1402 1463 1443 1487 1566

Sequent Scientific Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 27 3 23 22 20 44 40 68 68 54 57
Cash Flow from Operating Activities -4 -45 -24 -0 -7 45 116 115 115 31 17
Cash Flow from Investing Activities -55 -80 -155 -316 -116 7 -68 -72 10 -96 -65
Cash Flow from Financing Activities 35 146 179 309 147 -57 -20 -43 -139 67 32
Net Cash Inflow / Outflow -24 21 1 -7 24 -5 28 0 -14 2 -16
Closing Cash & Cash Equivalent 3 23 22 20 44 40 68 68 54 57 42

Sequent Scientific Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) -5.52 -8.26 -0.7 -0.78 -0.57 17.3 1.97 2.81 3.84 1.65 -4.86
CEPS(Rs) -3.28 -6.08 -2.29 1.17 1.08 2.11 4 5.34 6.24 3.88 -2.66
DPS(Rs) 0 0 0 0 0 0.2 0.2 0 0.5 0 0
Book NAV/Share(Rs) 7.09 1.97 3.76 38.69 39.44 25.85 27.86 27.1 28.98 25.97 25.76
Core EBITDA Margin(%) -4.58 1.91 3.91 8.88 6.23 9.77 11.8 14.14 15.13 7.59 0.82
EBIT Margin(%) -12.19 -18.35 -4.39 3.66 2.02 6.68 8.66 10.77 11.6 4.76 -7.02
Pre Tax Margin(%) -21.98 -26.42 -13.67 -2.48 -2.09 2.78 5.56 7.81 9.84 3.67 -9.47
PAT Margin (%) -19.62 -26.56 -14.4 -2.89 -2.01 1.2 5.37 6.81 7.53 3.1 -8.39
Cash Profit Margin (%) -11.25 -19.56 -7.54 4.47 3.8 6.07 9.33 11.01 11.17 6.68 -4.56
ROA(%) -11.65 -18.15 -8.62 -1.46 -0.81 0.63 4.14 5.73 7.19 3.06 -7.99
ROE(%) -65.24 -201.43 -159.4 -3.67 -1.47 1.28 8.63 12.06 15 6.56 -18.95
ROCE(%) -10.46 -17.29 -3.91 2.5 1.05 4.84 9.24 12.59 16.24 7.01 -9.71
Receivable days 72.7 65.64 78.37 90.4 118.4 110.21 92.53 90.45 87.43 85.48 84.11
Inventory Days 82.12 82.19 77.1 67.38 78.37 68.62 61.85 63.56 63.61 77.5 87.1
Payable days 276.03 229.13 166.52 143.31 177.53 143.55 124.3 129.62 117.51 111.61 109.97
PER(x) 0 0 0 0 0 4.47 36.45 27.61 62.69 81.14 0
Price/Book(x) 3.66 19.27 27.2 3.78 3.27 2.99 2.58 2.87 8.31 5.15 2.82
Dividend Yield(%) 0 0 0 0 0 0.26 0.28 0 0.21 0 0
EV/Net Sales(x) 1.78 2.25 4.5 6.23 5.13 2.53 1.95 1.86 4.52 2.53 1.52
EV/Core EBITDA(x) -44.52 75.57 71.04 55.13 64.95 21.58 15.17 12.18 27.91 29.76 118.11
Net Sales Growth(%) -5.48 20.85 12.21 36.77 12.76 24.03 22.58 13.46 15.47 3.76 0.57
EBIT Growth(%) -269.65 -82.71 73.3 211.85 -38.68 306.58 61.66 41.56 24.06 -57.33 -248.67
PAT Growth(%) -4497.88 -64.39 39.51 73.07 22.83 173.49 458.27 44.25 27.31 -57.14 -372.49
EPS Growth(%) -4110.53 -49.71 91.48 -10.04 26.83 3149.38 -88.6 42.79 36.53 -57.09 -394.57
Debt/Equity(x) 3.74 15.86 8.26 0.34 0.43 0.48 0.47 0.51 0.31 0.49 0.62
Current Ratio(x) 0.67 0.66 0.76 1.64 1.09 1.25 1.38 1.41 1.49 1.5 1.45
Quick Ratio(x) 0.42 0.41 0.53 1.17 0.8 0.88 0.92 0.98 0.98 0.86 0.83
Interest Cover(x) -1.25 -2.27 -0.47 0.6 0.49 1.72 2.8 3.63 6.6 4.36 -2.88
Total Debt/Mcap(x) 1 0.81 0.3 0.09 0.13 0.16 0.18 0.18 0.04 0.09 0.22

Sequent Scientific Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 53.02 53.02 52.79 52.79 52.79 52.79 52.79 52.79 52.79 52.79
FII 6.42 5.84 6.45 6.57 6.25 5.9 6.26 6.03 6.12 6.16
DII 2.13 2.04 2.26 2.79 2.81 2.92 2.92 3.23 7.23 7.59
Public 38.43 39.1 38.49 37.86 38.15 38.39 38.03 37.95 33.86 33.45
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 111.61 to 109.97days.

Cons

  • Company has a low return on equity of 1% over the last 3 years.
  • Stock is trading at 4.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Sequent Scientific News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!